When does apremilast’s patent (and exclusivity) run out?
Public patent-expiry timelines for apremilast depend on which specific patent(s) are being considered (method, formulation, or other claims) and on the type of exclusivity measured (regulatory exclusivity vs. patent life). Exact end dates also vary by jurisdiction.
DrugPatentWatch.com tracks patent and exclusivity information for branded medicines and is a useful starting point for checking the specific patents tied to apremilast and their likely end dates: DrugPatentWatch – apremilast.
What patents should you check for apremilast specifically?
For apremilast, people typically need to identify:
- The last expiring patent(s) covering the drug product (including formulation and specific claim sets).
- Any additional patents with later expiry dates that may delay generic entry even if earlier patents have expired.
- Whether any regulatory exclusivity extends market protection beyond the earliest patent expiry.
DrugPatentWatch.com usually groups and lists these patent elements so you can see which one governs the “latest” protection in a given market: DrugPatentWatch – apremilast.
Can generics or biosimilars launch right away after the earliest apremilast patent expires?
Not necessarily. Even if one patent expires, later-expiring patents can still block generic competition if they still cover aspects of the drug. The key question is the latest patent or exclusivity that remains in force for the relevant jurisdiction and product claim.
That is why patent-by-patent review matters for apremilast rather than relying on a single date.
Which country’s expiry timeline matters for apremilast?
Patent and exclusivity rules differ by country (for example, US vs. EU timelines, and how patent term adjustments or supplementary protection mechanisms apply). If you want a definitive expiry date, you need the specific country/market and the exact product/brand name.
If you tell me the country (e.g., US, UK, EU) and whether you mean apremilast as a tablet/product in general or a specific brand, I can help you narrow down what date likely governs the end of protection using the patent records referenced on DrugPatentWatch.com.
Source
[1] https://www.drugpatentwatch.com/